Zacks: Analysts Anticipate Syros Pharmaceuticals Inc (NASDAQ:SYRS) to Announce -$0.51 Earnings Per Share

Analysts forecast that Syros Pharmaceuticals Inc (NASDAQ:SYRS) will announce ($0.51) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Five analysts have made estimates for Syros Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.63) and the highest is ($0.46). Syros Pharmaceuticals posted earnings of ($0.47) per share in the same quarter last year, which suggests a negative year-over-year growth rate of 8.5%. The company is expected to issue its next earnings report on Thursday, November 7th.

On average, analysts expect that Syros Pharmaceuticals will report full-year earnings of ($1.94) per share for the current fiscal year, with EPS estimates ranging from ($2.07) to ($1.84). For the next fiscal year, analysts expect that the company will post earnings of ($1.97) per share, with EPS estimates ranging from ($2.34) to ($1.68). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for Syros Pharmaceuticals.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($0.47) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.41) by ($0.06). Syros Pharmaceuticals had a negative return on equity of 79.79% and a negative net margin of 3,137.55%. The firm had revenue of $0.46 million for the quarter, compared to analysts’ expectations of $0.42 million.

SYRS has been the subject of a number of recent research reports. HC Wainwright reaffirmed a “neutral” rating on shares of Syros Pharmaceuticals in a research note on Thursday, May 2nd. Zacks Investment Research downgraded Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday. ValuEngine raised Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, June 26th. BidaskClub raised Syros Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, July 12th. Finally, Wedbush reaffirmed an “outperform” rating and set a $13.00 price target on shares of Syros Pharmaceuticals in a research note on Thursday, April 25th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $16.03.

In other news, major shareholder Venture Fund Vii L.P. Arch sold 63,000 shares of the stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $7.77, for a total transaction of $489,510.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 14.80% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of SYRS. BlackRock Inc. grew its holdings in Syros Pharmaceuticals by 23.1% in the 4th quarter. BlackRock Inc. now owns 1,986,130 shares of the company’s stock valued at $11,063,000 after buying an additional 372,462 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in Syros Pharmaceuticals by 8.9% in the 4th quarter. Bank of New York Mellon Corp now owns 84,537 shares of the company’s stock valued at $470,000 after buying an additional 6,883 shares during the last quarter. Northern Trust Corp grew its holdings in Syros Pharmaceuticals by 0.7% in the 4th quarter. Northern Trust Corp now owns 306,167 shares of the company’s stock valued at $1,705,000 after buying an additional 2,179 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in Syros Pharmaceuticals by 62.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 244,080 shares of the company’s stock valued at $1,360,000 after buying an additional 93,728 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Syros Pharmaceuticals by 10.3% in the 4th quarter. Geode Capital Management LLC now owns 249,668 shares of the company’s stock worth $1,390,000 after acquiring an additional 23,234 shares during the period. 65.27% of the stock is currently owned by institutional investors and hedge funds.

Shares of SYRS traded up $1.23 during midday trading on Friday, reaching $11.08. 312,600 shares of the stock were exchanged, compared to its average volume of 179,558. Syros Pharmaceuticals has a 12-month low of $5.17 and a 12-month high of $13.16. The firm has a 50 day simple moving average of $8.25 and a 200-day simple moving average of $7.35. The company has a quick ratio of 8.11, a current ratio of 8.11 and a debt-to-equity ratio of 0.15. The company has a market cap of $372.18 million, a price-to-earnings ratio of -5.80 and a beta of 1.94.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients.

Featured Article: Capital gains and your 401(k) or IRA

Get a free copy of the Zacks research report on Syros Pharmaceuticals (SYRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.